We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

1,523 hedge funds and large institutions have $63.3B invested in Bristol-Myers Squibb in 2016 Q3 according to their latest regulatory filings, with 110 funds opening new positions, 663 increasing their positions, 548 reducing their positions, and 147 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 663 | Existing positions reduced: 548

3.14% less ownership

Funds ownership: 73.94%70.8% (-3.1%)

3% less funds holding

Funds holding: 1,5771,523 (-54)

17% less call options, than puts

Call options by funds: $1.15B | Put options by funds: $1.38B

25% less first-time investments, than exits

New positions opened: 110 | Existing positions closed: 147

30% less capital invested

Capital invested by funds: $90.9B → $63.3B (-$27.6B)

55% less funds holding in top 10

Funds holding in top 10: 11049 (-61)

Holders
1,523
Holders Change
-54
Holders Change %
-3.42%
% of All Funds
40.62%
Holding in Top 10
49
Holding in Top 10 Change
-61
Holding in Top 10 Change %
-55.45%
% of All Funds
1.31%
New
110
Increased
663
Reduced
548
Closed
147
Calls
$1.15B
Puts
$1.38B
Net Calls
-$227M
Net Calls Change
-$366M
Name Holding Trade Value Shares
Change
Change in
Stake
BMO
926
Beck Mack & Oliver
New York
$903K -$1.79M -27,940 -63%
LP
927
LMR Partners
United Kingdom
$900K -$19.9K -310 -2%
CCMW
928
Cypress Capital Management (Wyoming)
Wyoming
$897K +$3.21K +50 +0.3%
VFA
929
Voya Financial Advisors
Connecticut
$897K -$17.8K -277 -2%
AFG
930
Albion Financial Group
Utah
$897K +$597K +9,300 +127%
CAM
931
Columbia Asset Management
Michigan
$894K -$51.1K -795 -5%
OMC
932
Overbrook Management Corp
New York
$893K +$494K +7,695 +87%
TA
933
Tiedemann Advisors
New York
$892K +$1.15M +17,920 New
OCM
934
Osterweis Capital Management
California
$889K -$10.6K -165 -1%
BST
935
Bath Savings Trust
Maine
$885K -$4.5K -70 -0.4%
GD
936
Grandfield & Dodd
New York
$885K
BFC
937
Blue Fin Capital
Rhode Island
$883K +$16.1K +250 +2%
WDA
938
Wendell David Associates
New Hampshire
$878K
PP
939
Prudential plc
United Kingdom
$878K +$139K +2,159 +15%
ACM
940
Alethea Capital Management
Washington
$878K +$1.05M +16,283 New
IC
941
Inverness Counsel
New York
$877K -$93.8K -1,460 -8%
DCM
942
Donaldson Capital Management
Indiana
$876K -$218K -3,399 -17%
PGIM
943
Pacific Global Investment Management
California
$875K +$85K +1,323 +9%
CG
944
Caprock Group
Idaho
$874K -$10.1K -157 -1%
AI
945
Accredited Investors
Minnesota
$873K -$15.6K -243 -1%
CBN
946
Cadence Bank NA
Texas
$871K -$18.2K -283 -2%
FTC
947
Farmers Trust Company
Ohio
$870K -$117K -1,827 -10%
TSW
948
Thompson Siegel & Walmsley
Virginia
$870K -$7.39K -115 -0.7%
ED
949
Exane Derivatives
France
$870K +$867K +13,491 +511%
ZIC
950
ZWJ Investment Counsel
Georgia
$868K +$27.4K +427 +3%

BMY Hedge Fund Activity: Q3 2016 in Review

1,523 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q3 2016, worth a combined $63.3B — down 30% from $90.9B a quarter earlier.

Sellers outnumbered buyers: 147 funds closed out of BMY and 110 opened new positions — a net loss of 37 holders — while 548 trimmed existing stakes and 663 added.

The largest buyer was Wellington Management Group, adding an estimated $437M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.74B.

  • 1,523 institutional investors held Bristol-Myers Squibb (BMY) as of Q3 2016, down from 1,577 in Q2 2016.
  • Funds reported $63.3B of Bristol-Myers Squibb stock for Q3 2016, down 30% quarter-over-quarter.
  • 110 funds opened new Bristol-Myers Squibb positions in Q3 2016 and 147 closed out, a net change of -37 holders.
  • The largest Bristol-Myers Squibb buyer in Q3 2016 was Wellington Management Group, an estimated $437M added.
  • The largest Bristol-Myers Squibb seller in Q3 2016 was T. Rowe Price Associates, an estimated $1.74B sold.

Based on aggregated 13F filings for Q3 2016.